RT Journal Article
SR Electronic
T1 Estimating the Asymptomatic Ratio of 2019 Novel Coronavirus onboard the Princess Cruises Ship, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.20.20025866
DO 10.1101/2020.02.20.20025866
A1 Mizumoto, Kenji
A1 Kagaya, Katsushi
A1 Zarebski, Alexander
A1 Chowell, Gerardo
YR 2020
UL http://medrxiv.org/content/early/2020/02/23/2020.02.20.20025866.abstract
AB Potential transmissibility of asymptomatic 2019 Novel Coronavirus infection and a substantial asymptomatic ratio have been reported in clinical studies. Employing a statistical modeling analysis, we derived a delay-adjusted asymptomatic ratio of the positive 2019-nCoV infections onboard the Princess Cruises ship along with the timeline of infections. We estimated the percentage of cases that are asymptomatic to be 34.6% (95% CrI: 29.4%–39.8%), with most of the infections occurring before the start of the 2-week quarantine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKM acknowledges support from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 18K17368 and from the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan. KK acknowledges support from the JSPS KAKENHI Grant Number 18K19336 and 19H05330. AZ acknowledges supports from the Oxford Martin School Programme on Pandemic Genomics. GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases programAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe present study relies on published data and access information to essential components of the data are available from the corresponding author.